Learn about VE303, a potential first-in-class Live Biotherapeutic Product for preventing recurrent Clostridioides difficile ...

Discover the groundbreaking AI-based platform that designs peptides to target and destroy previously 'undruggable' ...

Johnson & Johnson is advancing Alzheimer’s research through precision medicine, focusing on tau-targeting therapies like ...

ITM announces positive Phase 3 results for ITM-11 in neuroendocrine tumours, paving the way for a potential new treatment ...

Glox Therapeutics secures £500K from a £3M fund to develop antibiotics targeting antimicrobial-resistant lung infections in ...

Casdozokitug, combined with atezolizumab and bevacizumab, shows durable responses and a 17.2% complete response rate in HCC ...

Grifols has received a $21 million grant from The Michael J. Fox Foundation to fund a pioneering study aimed at identifying ...

Learn about the gut-brain connection in mental health and how targeting serotonin in the gut could revolutionise ...

UVA researchers found that continuous glucose monitor data can predict nerve, eye, and kidney damage from type 1 diabetes.

Rigel Pharmaceuticals has enrolled the first patient in a Phase I trial to evaluate fostamatinib as a treatment for sickle ...

New cell therapy, Cilta-cel, shows promise in the treatment of multiple myeloma, providing a personalised approach with the ...

Cancer Research UK, Cytovation, and the Norwegian Cancer Society collaborate to advance treatment for adrenocortical ...